SUMMARY Using the '8f-fluoro-2-deoxy-d-glucose technique and positron emission tomography (PET), the local cerebral glucose utilisation (lCMRGlc) was measured in four non-demented patients with early-onset, bilateral Parkinson's disease characterised by the predominance of akinesia. The study was done twice, first in the untreated condition, and then after levodopa had been resumed. Despite a marked clinical improvement, we found no alteration in lCMRGlc between the first and second studies in any of the brain structure analysed. Compared to control values, lCMRGlc in the basal ganglia was moderately increased in both studies. These essentially negative findings agree with most previous human or animal studies, and indicate that the functional alterations in the central dopaminergic systems of patients with Parkinson's disease have metabolic correlates that are too small to be demonstrated by current PET devices.
The typical symptomatic triad of Parkinson's disease, that is akinesia, rigidity, and tremor, implies that functional alterations take place in certain cerebral structures. Since energy metabolism in the brain has been shown to be coupled to function,' changes in regional energy mnetabolism specific to the functional abnormalitves of Parkinson's disease might be expected to occur. Such changes should be found in the structures deprived of their normal dopaminergic afferences, principally the striatum2 and the cortico-limbic areas3 and, as a secondary effect, in the structures receiving projections from these structures.
In the attempt to use local energy metabolism as a marker of disordered dopaminergic transmission systems, several studies of the local cerebral glucose utilisation (lCMRGlc) using '4C-2-deoxy-D-glucose ('4CDG) autoradiography in rats with unilateral destruction of the dopaminergic systems have failed to show any consistent pattern of changes,4-9 although some reported striking alterations.4 5 Human studies of Parkinson' s disease patients have been, for methodological reasons, restricted to 2-dimensional '33xenon regional cerebral blood flow (rCBF)'0- '2 or oxygen-1513 investigations, but again have provided discrepant results.
Because it allows non-invasive 3-dimensional quantitative measurement of lCMRGlc in humans, positron emission tomography (PET) was used in the present work to investigate further this issue. Our protocol was essentially designed to see whether, in a small series of levodopa responders acting as their own controls, levodopa therapy would have any discernible effect on lCMRGlc.
Patients
Four severely affected non-demented male patients volunteered for the study (table 1). They were asked to participate in the investigation because of expected severe degeneration of central dopaminergic systems as suggested by: early onset of the disease, marked severity of akinesia with varying degree of rigidity and tremor, excellent response to levodopa therapy, and early occurrence of levodopa-induced adverse reactions such as on-off phenomena and abnormal involuntary movements. Each patient underwent in the fasting state two PET studies, the first 48 hours after all treatment had been stopped, and the second the next day, after treatment had been resumed for about 22 hours. In order to ensure reproducibility, repositioning of the patient' s head under the field of the positron camera was as accurate as possible, using laser beams projected on external landmarks on the forehead. Just After iv injection (over about 20 seconds) of "8FDG (3-6 mCi), blood samples were collected using the time-frame advocated by Phelps et al,"6 and the heated-hand vein procedure was employed to obtain arterialised blood while avoiding arterial catheterisation."6 Injection of "8FDG was started only after proper arterialisation of venous blood was achieved, by comparing its oxygen content to that of arterial blood (single femoral puncture). The samples were immediately put on ice, and subsequently centrifuged to measure the "IF plasma concentrations in a well-counter calibrated for "IF and cross-calibrated with the ECAT system to ensure proper quantitation of lCMRGlc.'9 Five samples were also used to measure the plasma glucose content, and the average value (Cp) was used thereafter.
Two different approaches were carried out simultaneously to measure lCMRGlc. One approach was the classic in vivo autoradiographic paradigm,'5 '6 which uses the "FDG blood history (Cp*), Cp and the regional tissue "IF concentration (C*t) determined in the PET quantitative images obtained at times >45 min after iv injection. In this approach, we used the operational equation of Huang etal,'7 which includes the 4 FDG rate-constants (that is, k*' to k*4) measured by these authors in young healthy adults, and the lumped constant (LC = 0.42) derived empirically from the same studies.'7 To do this, PET images of three contiguous head levels (OM + 1-5 cm, OM +3-5 cm, OM +5*5 cm) parallel to the OM Line were obtained in each study at times >55 min, with routine care. for accurate quantitation being taken," and were subsequently transformed pixel by pixel into quantitative ICMRGlc images.
In this approach, however, the assumption is made that the real k* values of our Parkinson's disease patients do not deviate much from the standard k* values used in the autoradiographic operational equation. It has been shown20 that inaccurate lCMRGlc may obtain if this assumption is not true. We therefore chose to measure regionally the real k* values and hence the "true" lCMRGlc in our Parkinson' s disease studies, using the method originally described for "4CDG in rats by Sokoloff et One potential inaccuracy in the kinetic method results from the presence of significant amounts of intra-vascular "8FDG in the initial PET scans. To avoid the increase of both dosimetry and examination time of an additional cerebral blood volume PET scan, we devised a standardised, time variable percent correction of the elementry "IF tissue curves for vascular "IF activity (using published data"6), a correction which should be quite acceptable for the present purposes. Generally, excellent fitting of the corrected "IF curves was achieved within 20-30 iterations.
Occasionally, however, statistical fluctuations due to low count-rates in the initial "8FDG scans induced slower convergence and/or less optimal fit. Nevertheless caudate and lenticular nuclei were significantly higher than controls. Although these discrepancies would appear to weaken the pathophysiological relevance of such findings, the lenticular and caudate values in both the treated and the untreated conditions and using both methods, were consistently higher than controls values, albeit not always significantly so (table 4, fig 3) . Perhaps studying larger series of Parkinson's disease patients and using a PET device of improved spatial resolution (to minimise the partial volume effect26) would confirm this impression of higher metabolism in the basal ganglia of Parkinson's disease patients. It must be stressed, however, that the basal ganglia lCMRGlc was not influenced by levodopa (table 3) , and hence that the relationship between the above changes and the clinical condition appears at best marginal.
The main goal of the present study was to investigate the effects of levodopa on lCMRGlc in our patient sample. Despite dramatic clinical improvement afforded by reinstitution of therapy, no alteration in lCMRGlc was found in any of the brain structures analysed. Having used both the autoradiographic method and the presumably more reliable kinetic method'" further supports this negative finding.
Although no other study of lCMRGlc in Parkinson's disease patients has been published yet, our negative findings are consonant with previously published studies of rCBF in Parkinson's disease patients. In 26 Parkinson's disease patients, two weeks of levodopa therapy induced no modification of rCBF ("33Xe inhalation technique).'0 In another study, using the same technique, a moderate but significant diffuse reduction in rCBF in 60 Parkinson's disease patients (both treated and untreated) compared to aged-matched controls was reported, but this reduction was not seen in the young, earlyonset Parkinson' s disease patients subgroup." Recently, a similar reduction in rCBF (preferentially affecting the frontal cortex) was reported, but again early-onset Parkinson' s disease patients were spared.'2 If the normal couple between CBF and energy metabolism' 19 is maintained in Parkinson's disease, the above studies would indicate that cortical metabolism is unaffected in early-onset Parkinson's disease patients, and hence would agree with our findings, but that, on the other hand, late onset Parkinson' s disease is associated with diffuse or preferentially frontal hypo-metabolism.
In a semiquantitative study of relative cerebral perfusion and oxygen metabolism using oxygen-15 and 2-dimensional scintigrams, Lenzi et Our essentially negative findings in human Parkinson' s disease are also consonant with one quantitative autoradiographic study, showing no asymmetry of '4CDG retention in the brain of rats after unilateral 6-hydroxy-dopamine (6-OHDA) destruction of the substantia nigra.6 Likewise, in the same rat model of unilateral Parkinson's disease, no alteration in rCBF2 or cytochrome oxydase redox shifts28 were observed in any part of the brain. However, four more detailed studies of '4CDG uptake in brain autoradiograms of rats with unilateral 6-OHDA lesions of the substantia nigra or of the ventral tegmental area provided fairly consistent results suggesting a small (3-9%) reduction in CMRGlc in the ipsilateral striatum, and a larger CMRGlc increase in the ipsilateral pallidum (10-40%) and lateral habenular nucleus (8-24%), while smaller changes were inconsistently seen in other structures.5 7-9 That these alterations in lCMRGlc resulted from lesions of the DA systems was shown by their absence in 6-OHDA lesioned rats treated with the DA agonist apomorphine.57 (Only after extensive 6-OHDA or electrolytic lesions of the mesencephalic tegmentum or lateral hypothalamus were marked decreases in ipsilateral frontal cortex lCMRGlc, unaltered by treatment with apomorphine, observed.4 5) To the best of our knowledge, there has been no study of the acute effects of levodopa on lCMRGlc in rats with unilateral 6-OHDA lesions of the substantia nigra. When administered to normal rats, levodopa-induced changes in the relative pattern of '4CDG distribution in brain that were difficult to interpret.29 Apomorphine, however, when given to normal rats, increased lCMRGlc in the caudate nucleus in a dose-dependent manner -an effect opposite to that of 6-OHDA nigro-striatal lesion-and decreased ICMRGlc in the anterior cingulate cortex.30 Taken together, therefore, the above animal studies suggested that ascending dopaminergic systems have presumably direct effects chiefly on striatal and lateral habenula glucose utilisation (stimulation and deprivation of dopaminergic transmission increasing and decreasing lCMRGlc, respectively) and presumably indirect metabolic effects on the pallidum (most likely though the striato-pallidal projections). These metabolic effects, however, remain relatively small.
No such changes were found in the present PET study of Parkinson's disease patients. This discrepancy may result from several differences between our human study and the above animal experiments. 
